LXRX LEXICON PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1062822 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.6%
TTM net income YoY9.1%
TTM EPS YoY21.1%
Revenue 3-yr CAGR317.1%
Net income 3-yr CAGR—
Margins
Gross margin98.9%
Operating margin-147.4%
Net margin-161.8%
FCF margin—
EBITDA margin-146.3%
Returns
ROE-43.9%
ROA-27.8%
ROIC (approx.)-33.3%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets32.3%
Debt / equity0.32x
Current ratio10.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $11.25M | $692,000 | $21.10M | $5.49M | $14.18M | $28.87M | $1.26M | $26.55M |
| Cost of revenue | $79,000 | $39,000 | $108,000 | $201,000 | $10,000 | $33,000 | $30,000 | $348,000 |
| Gross profit | $11.17M | $653,000 | $20.99M | $5.29M | $14.17M | $28.83M | $1.23M | $26.21M |
| R&D expense | $16.20M | $17.44M | $12.76M | $11.31M | $18.76M | $15.75M | $15.30M | $26.68M |
| SG&A expense | $9.46M | $9.75M | $9.23M | $8.76M | $7.60M | $9.35M | $11.61M | $32.26M |
| Operating income | -$14.49M | -$26.54M | -$996,000 | -$14.78M | -$12.19M | $3.74M | -$25.68M | -$32.74M |
| Net income | -$14.01M | -$31.77M | -$1.04M | -$15.53M | -$12.77M | $3.25M | -$25.30M | -$33.77M |
| EBITDA | -$14.40M | -$26.44M | -$886,000 | -$14.66M | -$12.04M | $3.91M | -$25.50M | -$32.61M |
| EPS (basic) | -0.03 | -0.07 | 0.00 | — | -0.04 | 0.01 | -0.07 | — |
| EPS (diluted) | -0.03 | -0.07 | 0.00 | — | -0.04 | 0.01 | -0.07 | — |
| Weighted avg. shares (diluted) | 444.96M | 437.65M | 400.24M | — | 363.40M | 363.57M | 362.07M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $44.08M | $40.92M | $38.09M | $34.33M | $78.66M | $50.36M | $62.89M | $66.66M |
| Short-term investments | $139.12M | $149.69M | $132.57M | $61.90M | $66.29M | $117.64M | $131.95M | $171.30M |
| Receivables | $1.78M | $1.64M | $11.78M | $2.38M | $2.33M | $2.18M | $47.45M | $3.47M |
| Inventory | $1.21M | $1.20M | $276,000 | $281,000 | $158,000 | $168,000 | $201,000 | $231,000 |
| Current assets | $188.84M | $196.58M | $186.03M | $101.89M | $122.53M | $145.08M | $245.81M | $246.19M |
| PP&E, net | $1.56M | $1.65M | $1.75M | $1.86M | $1.98M | $2.13M | $2.31M | $2.48M |
| Goodwill | $44.54M | $44.54M | $44.54M | $44.54M | $44.54M | $44.54M | $44.54M | $44.54M |
| Total assets | $242.02M | $250.06M | $268.82M | $184.99M | $205.93M | $225.58M | $297.67M | $298.42M |
| Current liabilities | $17.77M | $14.71M | $9.90M | $20.87M | $21.72M | $34.84M | $110.69M | $45.25M |
| Short-term debt | $0 | $0 | $0 | $4.59M | — | — | $42.06M | $0 |
| Long-term debt | $51.89M | $51.44M | $49.68M | $49.41M | $56.51M | $56.11M | $58.64M | $100.30M |
| Total debt | $51.89M | $51.44M | $49.68M | $54.00M | $56.51M | $56.11M | $100.70M | $100.30M |
| Total liabilities | $78.18M | $75.53M | $65.96M | $77.45M | $85.77M | $96.14M | $174.64M | $152.47M |
| Shareholders' equity | $163.84M | $174.53M | $202.86M | $107.54M | $120.16M | $129.44M | $123.03M | $145.95M |
| Net debt | $7.81M | $10.51M | $11.60M | $19.68M | -$22.15M | $5.74M | $37.81M | $33.64M |
| Shares outstanding | 446.91M | 446.87M | 425.71M | 365.85M | 365.78M | — | — | 363.02M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.08M | -$9.19M | -$14.73M | -$17.23M | -$23.83M | $16.99M | -$43.78M | -$21.49M |
| Capital expenditure | — | — | — | $0 | $0 | — | — | $474,000 |
| Free cash flow | — | — | — | -$17.23M | -$23.83M | — | — | -$21.96M |
| Investing cash flow | $11.18M | -$16.46M | -$70.26M | $4.83M | $52.12M | $15.48M | $40.58M | $53.70M |
| Financing cash flow | $55,000 | -$512,000 | $88.76M | -$2.93M | $0 | -$45.00M | -$572,000 | -$104,000 |
| Depreciation & amortization | $95,000 | $102,000 | $110,000 | $118,000 | $151,000 | $176,000 | $176,000 | $125,000 |
| Stock-based compensation | $3.40M | $3.30M | $3.08M | $2.83M | $3.40M | $3.20M | $3.04M | $1.54M |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.